DE68929351D1 - Wellenlängenspezifisches, cytotoxisches Mittel - Google Patents

Wellenlängenspezifisches, cytotoxisches Mittel

Info

Publication number
DE68929351D1
DE68929351D1 DE68929351T DE68929351T DE68929351D1 DE 68929351 D1 DE68929351 D1 DE 68929351D1 DE 68929351 T DE68929351 T DE 68929351T DE 68929351 T DE68929351 T DE 68929351T DE 68929351 D1 DE68929351 D1 DE 68929351D1
Authority
DE
Germany
Prior art keywords
specific
tissues
cells
wavelength
cytotoxic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929351T
Other languages
English (en)
Other versions
DE68929351T2 (de
Inventor
Julia G Levy
David Dolphin
Jack K Chow
Ethan Sternberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE68929351D1 publication Critical patent/DE68929351D1/de
Publication of DE68929351T2 publication Critical patent/DE68929351T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
DE68929351T 1988-07-19 1989-07-19 Wellenlängenspezifisches, cytotoxisches Mittel Expired - Lifetime DE68929351T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,161 US4920143A (en) 1987-04-23 1988-07-19 Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents

Publications (2)

Publication Number Publication Date
DE68929351D1 true DE68929351D1 (de) 2002-01-10
DE68929351T2 DE68929351T2 (de) 2002-05-08

Family

ID=22826617

Family Applications (3)

Application Number Title Priority Date Filing Date
DE2001199008 Active DE10199008I2 (de) 1988-07-19 1989-07-19 Wellenl{ngenspeziphisches, cytotoxisches Mittel.
DE68929351T Expired - Lifetime DE68929351T2 (de) 1988-07-19 1989-07-19 Wellenlängenspezifisches, cytotoxisches Mittel
DE68924215T Expired - Lifetime DE68924215T2 (de) 1988-07-19 1989-07-19 Wellenlängenspeziphisches, cytotoxisches Mittel.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2001199008 Active DE10199008I2 (de) 1988-07-19 1989-07-19 Wellenl{ngenspeziphisches, cytotoxisches Mittel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68924215T Expired - Lifetime DE68924215T2 (de) 1988-07-19 1989-07-19 Wellenlängenspeziphisches, cytotoxisches Mittel.

Country Status (10)

Country Link
US (1) US4920143A (de)
EP (2) EP0352076B1 (de)
AT (2) ATE209650T1 (de)
AU (1) AU638675B2 (de)
CA (1) CA1339927C (de)
DE (3) DE10199008I2 (de)
ES (2) ES2169060T3 (de)
GR (1) GR3017426T3 (de)
LU (1) LU90718I2 (de)
NL (1) NL300037I2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
USRE39094E1 (en) * 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
AU641658B2 (en) * 1989-06-07 1993-09-30 University Of British Columbia, The Photosensitizing diels-alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
GB9014307D0 (en) * 1990-06-27 1990-08-15 Scient Generics Ltd Method of treatment and compositions therefor
US5219878A (en) * 1990-10-05 1993-06-15 Queen's University Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents
US5435307A (en) * 1991-03-29 1995-07-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Surface fluorescent monitor
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
CA2097280A1 (en) * 1992-06-01 1993-12-02 Sandor G. Vari Apparatus and method of use for a photosensitizer enhanced fluorescence based bipsy needle
EP0654993A1 (de) * 1992-08-17 1995-05-31 Quadra Logic Technologies Inc. Verfahren zur Zerstörung oder Hemmung unerwünschter Zellen oder Gewebe
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
ITFI940095A1 (it) * 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
DE19514088A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
WO1997026885A1 (en) * 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
WO1999013943A1 (en) 1996-03-05 1999-03-25 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5693789A (en) * 1996-04-10 1997-12-02 Abbott Laboratories Process for the preparation of a protoporphyrin
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
CZ294715B6 (cs) * 1997-05-07 2005-02-16 Qlt Inc. Ethylenglykol estery monohydrobenzoporfyrinových derivátů jako fotoaktivní činidla
PL202340B1 (pl) * 1997-05-07 2009-06-30 Univ British Columbia Pochodna benzoporfiryny, sposób jej wytwarzania, kompozycja farmaceutyczna ją zawierająca oraz jej zastosowanie jako czynnika fotoaktywnego
WO1999004857A1 (de) 1997-07-28 1999-02-04 Novartis Ag Vorrichtung und verfahren zum bestrahlen eines auges eines patienten für eine photodynamische therapie
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
WO1999034839A1 (en) 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000061585A2 (en) * 1999-04-14 2000-10-19 The University Of British Columbia (Ubc) 1,3-dipolar cycloadditions to polypyrrolic macrocycles
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
AU5040101A (en) * 2000-03-24 2001-10-15 Novartis Ag Improved treatment of neovascularization
WO2001085213A2 (en) 2000-05-08 2001-11-15 The University Of British Columbia Supports for photosensitizer formulations
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
DE60219627T2 (de) 2001-06-04 2008-02-07 The General Hospital Corp., Boston Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
EP1465590B1 (de) * 2001-11-02 2008-03-26 The Governors Of The University Of Alberta Micelle-zusammensetzungen enthaltend pegylierten phospholipide und einen photosensibilisator
DE60225169D1 (de) * 2001-11-09 2008-04-03 Quadra Logic Tech Inc Photodynamische therapie zur behandlung von haarausfall
DE60307545T2 (de) * 2002-06-21 2007-10-04 Adair, Edwin L., Castle Pines Village Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose
AU2003301267A1 (en) * 2002-10-18 2004-05-04 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
WO2006050328A1 (en) 2004-10-29 2006-05-11 Cerus Corporation Improved quenching methods for red blood cell inactivation process
AU2009233807B2 (en) 2008-04-09 2014-11-27 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
MX2013008175A (es) 2011-01-13 2013-12-16 Quadra Logic Tech Inc Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
BR112014022228A2 (pt) 2012-03-08 2017-07-11 Halozyme Inc anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos
CN104703624A (zh) 2012-07-11 2015-06-10 德米拉股份有限公司 局部递送光敏剂的药物组合物及其应用
EP3044236A2 (de) 2013-09-12 2016-07-20 Halozyme, Inc. Modifizierte anti-egfr-antikörper und verfahren zur verwendung davon
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
JP7155144B2 (ja) 2017-03-14 2022-10-18 オハイオ・ステイト・イノベーション・ファウンデーション 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951800A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes utilizing improved catalysts
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
WO1984001382A1 (en) * 1982-09-27 1984-04-12 Oncology Research & Dev Inc Purified hematoporphyrin derivative for diagnosis and treatment of tumors, and method
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents

Also Published As

Publication number Publication date
DE68929351T2 (de) 2002-05-08
DE10199008I1 (de) 2003-06-12
EP0352076B1 (de) 1995-09-13
CA1339927C (en) 1998-06-23
ATE127696T1 (de) 1995-09-15
NL300037I1 (nl) 2001-03-01
EP0352076A2 (de) 1990-01-24
DE68924215T2 (de) 1996-02-15
ATE209650T1 (de) 2001-12-15
DE68924215D1 (de) 1995-10-19
GR3017426T3 (en) 1995-12-31
ES2169060T3 (es) 2002-07-01
US4920143A (en) 1990-04-24
ES2080745T3 (es) 1996-02-16
AU638675B2 (en) 1993-07-08
LU90718I2 (fr) 2001-03-01
DE10199008I2 (de) 2004-10-14
EP0641796B1 (de) 2001-11-28
NL300037I2 (nl) 2001-08-01
AU3825889A (en) 1990-02-08
EP0641796A1 (de) 1995-03-08
EP0352076A3 (de) 1991-07-17

Similar Documents

Publication Publication Date Title
DE68924215T2 (de) Wellenlängenspeziphisches, cytotoxisches Mittel.
Fingar et al. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response
EP0947222B1 (de) Verfahren zur Aktivierung von photoempfindlichen Mitteln
JP2002522110A (ja) 光エネルギを用いた色素沈着組織の治療方法
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
HU220251B (hu) Fényérzékenyítő anyagok in vivo transzkután aktiválása a vérben
Biolo et al. Photodynamic therapy of B16 pigmented melanoma with liposome‐delivered Si (IV)‐naphthalocyanine
RU2006110554A (ru) Соединение для антимикробной фотодинамической терапии и способ применения
EP1120119A4 (de) Heilmittel für die photochemotherapie
Ash et al. Photodynamic therapy--achievements and prospects.
WO1992000106A3 (en) Method of treatment and compositions therefore
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
ATE87826T1 (de) Herstellung und verwendung von purpurinen, chlorinen und purpurin und chlorin enthaltenden zubereitungen.
US7122518B2 (en) Method for preventing or reducing collateral phototoxic damage to neighboring tissues during photodynamic therapy of a target tissue
Okuda et al. Experimental and clinical studies on HPD-photoradiation therapy for upper gastrointestinal cancer
AU3401093A (en) Therapeutic agent for threatened abortion
Davis et al. Effects of photosensitizer (hematoporphyrin derivative‐HPD) and light dose on vascular targets in the albino mouse ear
Berns et al. Porphyrin sensitized phototherapy
Lubart et al. A light source for phototherapy
Tomio et al. Effect of hematoporphyrin and red light on AH-130 solid tumors in rats
RU2146159C1 (ru) Способ фотодинамической терапии злокачественных новообразований
Abramson et al. Clinical exacerbation of systemic lupus erythematosus after photodynamic therapy of laryngotracheal papillomatosis
US6586419B1 (en) Phototherapeutic inactivation of ocular viruses
NO914837L (no) Fotosensitiserende diels-alder-porfyrinderivater
Nyamekye Vascular and other non-tumour applications of photodynamic therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition